Table I.
Characteristic | Patients (n=174) |
---|---|
Sex | |
Male | 90.2% (157/174) |
Female | 9.8% (17/174) |
Age, years | 55 (19–85) |
Ascites | 66.1% (115/174) |
Encephalopathy | 2.9% (5/174) |
Karnofsky performance status | 60 (20–90) |
Laboratory parameters | |
Leukocytes, ×109 cells/l | 6.84 (1.84–25.09) |
Neutrophils, ×109 cells/l | 4.89 (1.11–22.44) |
ALC, ×109 cells/l | 1.23 (0.32–4.18) |
AMC, ×109 cells/l | 0.60 (0.08–3.85) |
Hemoglobin, g/l | 115.3 (56.0–177.0) |
Platelets, ×109 cells/l | 156.3 (4.0–503.0) |
LMR | 2.57 (0.39–7.0) |
≤2.22 | 49.4% (86/174) |
>2.22 | 50.6% (88/174) |
3-Month mortality rate, % | 59.2% (103/174) |
6-Month mortality rate, % | 74.1% (129/174) |
Child-Pugh grade | |
0 | 20.7% (36/174) |
1 | 44.8% (78/174) |
2 | 34.5% (60/174) |
TNM stage | |
I | 9.8% (17/174) |
II | 11.5% (20/174) |
III | 56.3% (98/174) |
IV | 22.4% (39/174) |
Lymph node metastasis | 30.5% (53/174) |
Distant metastases | 20.7% (36/174) |
Portal vein thrombosis | 72.4% (126/174) |
NCCN-TNM | |
T1 | 10.9% (19/174) |
T2 | 13.8% (24/174) |
T3-T4 | 75.3% (131/174) |
ALC, absolute lymphocyte count; AMC, absolute monocyte count; LMR, lymphocyte-to-monocyte ratio; NCCN, National Comprehensive Cancer Network; TNM, tumor-node-metastasis.